Perioperative blood loss and gastrointestinal tolerability of etoricoxib and diclofenac in total hip arthroplasty (ETO-DIC study): a single-center, prospective, double-blinded randomized controlled trial

100 patients scheduled for total hip arthroplasty were randomized to receive either etoricoxib or diclofenac sodium (for perioperative analgesic treatment) and evaluated for drug-associated blood loss and incidence of gastrointestinal distress. The purpose of this study was to evaluate if treatment with etoricoxib lead to better outcomes compared to diclofenac. Results of this study demonstrated that etoricoxib did not display significantly lower blood loss or a significantly lower rate of gastrointestinal complications when compared to diclofenac in total hip arthroplasty.